Antibodies to NIMA interacting proteins

Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C530S388230, C530S388240, C530S389100, C424S130100, C424S141100, C424S145100

Reexamination Certificate

active

06596848

ABSTRACT:

FIELD OF THE INVENTION
The present invention relates generally to the eukaryotic cell cycle and specifically to a novel class of proteins that interact with NIMA protein kinase in the NIMA mitotic pathway.
BACKGROUND OF THE INVENTION
The CDC2 kinase associated with its cyclin partners has been shown to play an important role during G2/M progression in eukaryotic cells. However, recent studies demonstrate that activation of the CDC2 kinase itself is not sufficient to trigger mitosis in some eukaryotic cells such as those in
Saccharomyces cerevisiae
(Amon, et al.,
Nature
, 355:368, 1992; Sorger and Murray,
Nature
, 355:365, 1992; Stueland et al.,
Mol. Cell. Bio
., 13:3744, 1993) and
Aspergillus nidulans
(Osmani, et al.,
Cell
, 67:283, 1991a). Furthermore, detailed analysis of mouse oocyte maturation reveals that CDC2 histone H1 kinase activity does not increase during the G2/M transition as indicated by germinal vesicle breakdown (GVBD) (Choi, et al.,
Development
, 113:789, 1991; Jung, et al.,
Int. J. Dev. Biol
., 37:595, 1993; Gavin, et al.,
J. Cell Sci
., 107:275, 1994). These results suggest that there might be other mitotic activation pathway(s) remaining to be identified.
Recent studies have identified a novel mitotic kinase, NIMA, encoded by the Aspergillus nimA gene (Osmani, et al.,
Cell
, 53:237, 1988). NIMA kinase activity is tightly regulated during the nuclear division cycle, peaking in late G2 and M. Overexpression of NIMA promotes entry of Aspergillus cells into M (Osmani, et al.,
Cell
, 53:237, 1988; Lu and Means,
EMBO J
., 13:2103, 1994). Thus, NIMA is important for progression into mitosis in Aspergillus.
NIMA is a protein-Ser/Thr kinase, biochemically distinct from other protein kinases, and its phosphotransferase activity is regulated by Ser/Thr phosphorylation. It has recently been shown that the NIMA mitotic pathway is not restricted to Aspergillus, but also exists in vertebrate cells (Lu and Hunter,
Cell
, 81:413, 1995a). In Xenopus oocytes, NIMA induces germinal vesicle breakdown without activating Mos. CDC2 or MAP kinase. In HeLa cells, NIMA induces mitotic events without activating CDC2, whereas dominant-negative NIMA mutants cause a specific G2 arrest. In addition. O'Connell, et al (
EMBO J
, 13:4926, 1994) have also demonstrated that NIMA induce premature chromatin condensation in fission yeast and HeLa cells. These results reveal the existence of a NIMA-like mitotic pathway in other eukaryotic cells.
Peptidyl-prolyl cis/trans isomerases (PPIases, proline isomerases) are ubiquitously expressed enzymes catalyzing the cis/trans isomerization of the peptidyl-prolyl peptide bond which can be the rate-limiting step in protein folding or assembly under some circumstances. Cyclophilins and FK506-binding proteins (FKBPs) are two well characterized families of PPIases that share little if any amino acid similarity to each other. However, the members of each family contain a core structure that has been highly conserved from prokarvotes to eukarvotes. The importance of these PPIases is highlighted by the findings that cyclophilin and FK506-binding proteins are the targets of immuno-suppressive drugs cyclosporin A and FK506, respectively, and play an important role in cell signaling in T cell activation, although none of these genes have been shown to be essential for life (for review see Schreiber,
Science
, 251:283, 1991; Fruman, et al.,
FASEB J
., 8:391, 1994).
The recent discovery of parvulin has led to the identification of a third family of PPIases, which show little homology with either cyclophilins or FKBPs and is not sensitive to the immunosuppressive drugs (Rahfeld, et al.,
FEBS Lett
., 352:180, 1994a and
FEBS Lett
., 343:65, 1994b). A sequence homology search identified several other members of this family including those involved in protein maturation and/or transport and the ESS1 gene (Rudd, et al.,
TIBS
. 20:12, 1995). ESS1 is an essential gene for the growth in budding yeast and previous results suggested that it may be required at later stages of the cell cycle (Hanes, et al.,
Yeast
, 5:55, 1989). ESS1 was recently reisolated as PTF1 in a screen for genes involved in mRNA 3′ end maturation. Ptf1 was shown to contain a putative PPIase domain, but PPIase activity could not be demonstrated (Hani. et al.,
FEBS Lett
., 365:198, 1995). So far, none of the PPIases have been shown to be specifically involved in cell cycle control.
There is a need to identify components of the mammalian NIMA mitotic pathway in order to identify genes essential for life. Identification of such genes has several utilities including the identification of appropriate therapeutic targets, candidate genes for gene therapy (e.g, gene replacement), mapping locations of disease-associated genes, and for the identification of diagnostic and prognostic indicator genes, for example.
SUMMARY OF THE INVENTION
The present invention provides a novel class of proteins that associate with NIMA protein kinase. Some of these proteins are characterized by inhibiting the mitosis promoting function of NIMA when overexpressed and inducing mitotic arrest and nuclear fragmentation when depleted.
In a first embodiment, the invention provides an exemplary NIMA associated protein called “protein interacting with NIMA” (Pin1). Pin1 has C-terminal peptidylpropyl cis/trans isomerase activity and contains a conserved N-terminal tryptophan domain (WW domain) thought to mediate protein-protein interactions. Also included are polynucleotides encoding PIN proteins.
In another embodiment, the invention provides a method for identifying a protein that inhibits the mitosis promoting function of NIMA protein kinase. The method is based on a genetic system designed to detect protein-protein interactions. The method comprises culturing transformed cells containing the following: a nucleic acid construct comprising a DNA binding domain operatively associated with the coding sequence of NIMA, or functional fragments thereof; a nucleic acid library, wherein each member of said library comprises a transactivation domain operatively associated with a protein encoding sequence; and a nucleic acid reporter construct comprising a response element for the DNA binding domain operatively associated with a reporter gene, and monitoring for evidence of expression of reporter gene.
In yet another embodiment, the invention provides a method for controlling the growth of a cell comprising contacting the cell with a composition which modulates Pin1 activity. For example, an inhibitor of Pin1 activity such as a PPIase inhibitor or an anti-Pin1 antibody, or an inhibitor of PIN1 expression such as an antisense nucleotide sequence or a ribozyme, can be used to control growth of a cell. Alternatively, Pin1 activity can be increased by an activator or PIN1 expression can be increased by an enhancer, for example.
Finally, the invention provides a method for identifying a protein or other composition (e.g., drug or other small molecule) that associates with and/or modulates Pin1 protein activity or PIN1 gene expression.


REFERENCES:
patent: 5443962 (1995-08-01), Draetta et al.
Lambert-Messerlian et al, “Human Follicular Fluid Contains Pro- and C-Terminal Immunoreactive alpha-Inhibin Precursor Protein” vol. 78, No. 2, pp. 433-439, 1994.*
Engleman, ED. Human Hybridomos and Monoclonal Antibodies, Plenum Press, N.Y., 1985.*
Rosborough et al, Transplantation Proceedings, 1991, vol. 23, pp. 2890-2893.*
Livingston et al, PNAS, 1992, vol. 89, pp. 10974-10978. (abstract).*
Yoon et al, Molecular and Cellular biology, 1995, vol. 15, pp. 4835-4842. (abstract).*
Burgess et al “Possible Dissociation of the Heparin-binding and Mitogenic Acitivies of Heparin-binding Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a single Lysine Residue”, Journal of Cellular biology, vol. 111, pp, 1990.*
Lazar et al, “Transforming Growth Factor Alpha: Mutation of Aspartic Acid 47 and Leuine 48 Results in Different Biological Activities”, Molecular and Cellular Biology, vol. 8, pp. 1247-1252, 1988.*
Lu,

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Antibodies to NIMA interacting proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibodies to NIMA interacting proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to NIMA interacting proteins will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3057945

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.